Biotech's Positive Results
Everyone else may be talking about discovery-based biotechs, but the fact is, top-rated Goldman Sachs biotech analyst Maykin Ho told the February 6 Mayfield/Wilson Sonsini conference, "Financing the Biopharmaceutical Company," biotechs with clinical-stage products aren't doing badly.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.